ArticleFrontiers in neuroscience2026
Identification and validation of circadian rhythm and astrocyte-associated diagnostic and therapeutic model for cirrhosis encephalopathy patients via integrative bioinformatic pipelines and
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cirrhosis encephalopathy (CE) is a severe neuropsychiatric complication of liver cirrhosis, characterized by cognitive decline. While circadian rhythm (CR) disruption and astrocyte dysfunction are independently implicated, their integrated role in CE pathogenesis remains elusive. Methods: Limma and WGCNA analysis were performed for identification of CR and astrocyte (CA)-associated DEGs in CE patient bulk data (GSE41919 and GSE53808). Next, in 2 dependent CE patient bulk data (GSE184220 and GSE149741), we pinpointed CA-associated hub gene and nominated its corresponding diagnostic potential for CE patients via random forest (RF) machine learning algorithm. Next, molecular and immune patterns of hub gene in CE were examined in GSE184220 via single-gene GSEA and CIBERSORT analysis. Single-cell RNA-seq (GSE163577) from cognitive impairment patients was used to validate the cellular specificity of the hub gene and its functional implications in astrocyte via cutting-edge analytical framework, such as monocle2 and scTenifoldKnk analysis. Artificial intelligence (AI)-driven framework (DrugReflector) coupled with molecular docking identified a therapeutic compound in GSE41919 for the treatment of CE. Finally, an Results: IL8 can be considered as up-regulated CA-associated pathogenic factor involved in the pathogenesis of CE, which was predominantly active in astrocytes and related to neuroinflammation and CR regulation. AI-based drug screening nominated BRD-K11973162 as a potential therapeutic compound. Conclusion: This study discovered CA-related molecular patterns CE. IL18 emerges as a central pathogenic factor within astrocytes, providing a novel framework for risk stratification and targeted therapy for this debilitating condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.